{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:03Z","timestamp":1786986903634,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007192","name":"Rijksinstituut voor Volksgezondheid en Milieu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cmi.2025.09.027","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T09:13:10Z","timestamp":1763111590000},"page":"440-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact and vaccine effectiveness of the 23-valent pneumococcal polysaccharide vaccine in adults aged 65 years or older in the Netherlands"],"prefix":"10.1016","volume":"32","author":[{"given":"F.A.","family":"Niessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Steens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.H.","family":"Groenwold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"van Sorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.09.027_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","article-title":"Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions","volume":"22","author":"Shiri","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.cmi.2025.09.027_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijid.2015.05.003","article-title":"Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence","volume":"37","author":"Curcio","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib3","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1016\/j.vaccine.2019.08.025","article-title":"Twelve years of pneumococcal conjugate vaccination in the Netherlands: impact on incidence and clinical outcomes of invasive pneumococcal disease","volume":"37","author":"Vestjens","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.09.027_bib4","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.027_bib5","series-title":"Melker H.E. Pneumokokkenziekte in Nederland\u2014Achtergronddocument voor de Gezondheidsraad","author":"Knol","year":"2017"},{"key":"10.1016\/j.cmi.2025.09.027_bib6","unstructured":"Gezondheidsraad. Vaccinatie van ouderen tegen pneumokokken. Den Haag: Gezondheidsraad; 2018. Rapport nr. 2018\/05. Available from: https:\/\/www.gezondheidsraad.nl\/documenten\/2018\/02\/28\/vaccinatie-van-ouderen-tegen-pneumokokken"},{"key":"10.1016\/j.cmi.2025.09.027_bib7","unstructured":"Heins M.J., Korevaar J.C., Hooiveld M. Monitor vaccinatiegraad Nationaal programma pneumokokkenvaccinatie Volwassenen (NPPV) 2020. Utrecht: NIVEL; 2021. Available from: https:\/\/www.nivel.nl\/nl\/publicatie\/monitor-vaccinatiegraad-nationaal-programma-pneumokokkenvaccinatie-volwassenen-nppv-2020."},{"key":"10.1016\/j.cmi.2025.09.027_bib8","series-title":"Vaccine coverage Dutch National pneumococcal vaccination program adults 2021: brief monitor","author":"Heins","year":"2022"},{"key":"10.1016\/j.cmi.2025.09.027_bib9","unstructured":"Heins M.J., Knottnerus B., Matser A., Hooiveld M. Monitor vaccinatiegraad Nationaal programma pneumokokkenvaccinatie volwassenen (NPPV) 2022. Utrecht: Nivel; 2023. Available from: https:\/\/www.nivel.nl\/nl\/publicatie\/monitor-vaccinatiegraad-nationaal-programma-pneumokokkenvaccinatie-volwassenen-nppv-2022"},{"key":"10.1016\/j.cmi.2025.09.027_bib10","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.09.027_bib11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cmi.2025.09.027_bib12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.cmi.2025.09.027_bib13","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/600045","article-title":"Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome","volume":"49","author":"Jansen","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib14","unstructured":"C.E. (Katja) van Ewijk AA, Nina M. van Sorge, Anneke Steens. Evaluatie van surveillance systeem voor invasieve pneumokokkenziekte in volwassenen van 60 jaar en ouder, 2021-2022. Infectie Bulletin. 2024;BI 03. Available from: https:\/\/www.rivm.nl\/weblog\/ib-evaluatie-van-surveillance-systeem-voor-invasieve-pneumokokkenziekte-in-volwassenen-van-60"},{"key":"10.1016\/j.cmi.2025.09.027_bib15","first-page":"939","article-title":"Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme","volume":"46","author":"Smith","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cmi.2025.09.027_bib16","unstructured":"CBS StatLine; 2023. https:\/\/opendata.cbs.nl\/#\/CBS\/en\/. Accessed 1 June 2022."},{"key":"10.1016\/j.cmi.2025.09.027_bib17","doi-asserted-by":"crossref","first-page":"100126","DOI":"10.1016\/j.lanepe.2021.100126","article-title":"Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: a retrospective cohort study","volume":"7","author":"Perniciaro","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2025.09.027_bib18","doi-asserted-by":"crossref","first-page":"100409","DOI":"10.1016\/j.lanepe.2022.100409","article-title":"Correction to \u201cPneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: a retrospective cohort study","volume":"18","author":"Perniciaro","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2025.09.027_bib19","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.3201\/eid2610.191531","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017","volume":"26","author":"Shimbashi","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12879-020-05721-0","article-title":"Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan","volume":"21","author":"Su","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales","volume":"6","author":"Djennad","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2025.09.027_bib22","doi-asserted-by":"crossref","first-page":"20922","DOI":"10.2807\/1560-7917.ES2014.19.40.20922","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011","volume":"19","author":"Gutierrez Rodriguez","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2025.09.027_bib23","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1016\/j.vaccine.2019.04.017","article-title":"Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study","volume":"37","author":"Kim","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.09.027_bib24","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1016\/j.vaccine.2013.09.049","article-title":"Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011","volume":"31","author":"Rudnick","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.09.027_bib25","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10096-022-04513-5","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals \u2265 65 years of age: a Danish cohort study","volume":"41","author":"Nielsen","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/QCO.0b013e3283531b0f","article-title":"Use of pneumococcal polysaccharide vaccine in children: what is the evidence?","volume":"25","author":"Borrow","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/microorganisms10050972","article-title":"Pathogen- and type-specific changes in invasive bacterial disease epidemiology during the first year of the COVID-19 pandemic in the Netherlands","volume":"10","author":"Steens","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2025.09.027_bib29","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium","volume":"5","author":"Shaw","year":"2023","journal-title":"Lancet Digital Health"},{"key":"10.1016\/j.cmi.2025.09.027_bib30","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","article-title":"Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study","volume":"75","author":"Danino","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.027_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192640","article-title":"Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands","volume":"13","author":"Thorrington","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2025.09.027_bib32","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/13696998.2022.2152235","article-title":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23","volume":"25","author":"Olsen","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.cmi.2025.09.027_bib33","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3390\/vaccines10122032","article-title":"Cost-effectiveness of vaccination with the 20-valent pneumococcal conjugate vaccine in the Italian adult population","volume":"10","author":"Polistena","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2025.09.027_bib34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","article-title":"Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease","volume":"22","author":"Mendes","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcome Res"},{"key":"10.1016\/j.cmi.2025.09.027_bib35","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1016\/j.vaccine.2022.10.010","article-title":"Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly","volume":"40","author":"Hoshi","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.09.027_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","article-title":"Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands","volume":"22","author":"de Boer","year":"2024","journal-title":"BMC Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:20:33Z","timestamp":1785363633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1198743X25005531"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.027","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact and vaccine effectiveness of the 23-valent pneumococcal polysaccharide vaccine in adults aged 65 years or older in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}